The use of anti-CEA CAR-T cell therapy as local treatment of peritoneal carcinomatosis from mCRC has also been studied in pre-clinical trials [125] and several other studies are underway analyzing the further clinical impact of ACT in CRC (NCT03935893, NCT03970382, NCT04426669). Here, CEACAM5 is linked to colorectal carcinoma.